Akt-mediated Phosphorylation of Bmi1 Modulates Its Oncogenic Potential, E3 Ligase Activity, and DNA Damage Repair Activity in Mouse Prostate Cancer

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2012 Apr 17

PMID 22505453

Citations 73

Authors

Karim Nacerddine

Jean-Bernard Beaudry

Vasudeva Ginjala

Bart Westerman

Francesca Mattiroli

Ji-Ying Song

Henk van der Poel

Olga Balague Ponz

Colin Pritchard

Paulien Cornelissen-Steijger

John Zevenhoven

Ellen Tanger

Titia K Sixma

Shridar Ganesan

Maarten van Lohuizen

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is a major lethal malignancy in men, but the molecular events and their interplay underlying prostate carcinogenesis remain poorly understood. Epigenetic events and the upregulation of polycomb group silencing proteins including Bmi1 have been described to occur during PCa progression. Here, we found that conditional overexpression of Bmi1 in mice induced prostatic intraepithelial neoplasia, and elicited invasive adenocarcinoma when combined with PTEN haploinsufficiency. In addition, Bmi1 and the PI3K/Akt pathway were coactivated in a substantial fraction of human high-grade tumors. We found that Akt mediated Bmi1 phosphorylation, enhancing its oncogenic potential in an Ink4a/Arf-independent manner. This process also modulated the DNA damage response and affected genomic stability. Together, our findings demonstrate the etiological role of Bmi1 in PCa, unravel an oncogenic collaboration between Bmi1 and the PI3K/Akt pathway, and provide mechanistic insights into the modulation of Bmi1 function by phosphorylation during prostate carcinogenesis.

Citing Articles

Role of HIF-1α-Activated IL-22/IL-22R1/Bmi1 Signaling Modulates the Self-Renewal of Cardiac Stem Cells in Acute Myocardial Ischemia.

Lee W, Lin S, Chiang C, Chen J, Chieng W, Huang S Stem Cell Rev Rep. 2024; 20(8):2194-2214.

PMID: 39264501 PMC: 11554697. DOI: 10.1007/s12015-024-10774-8.

Genome-wide relaxation of selection and the evolution of the island syndrome in Orkney voles.

Wang X, Heckel G Genome Res. 2024; 34(6):851-862.

PMID: 38955466 PMC: 11293545. DOI: 10.1101/gr.278487.123.

Role of Stem Cells in the Pathogenesis and Malignant Transformation of Oral Submucous Fibrosis.

Kizhakkoottu S, Ramani P, Tilakaratne W Stem Cell Rev Rep. 2024; 20(6):1512-1520.

PMID: 38837114 DOI: 10.1007/s12015-024-10744-0.

Promotes the Proliferation and Migration of Gallbladder Cancer Cells via STRA6-Mediated Activation of PI3K/AKT Signaling.

Zhu X, Zhang Y, Bian R, Zhu J, Shi W, Ye Y Cancers (Basel). 2024; 16(4).

PMID: 38398143 PMC: 10887181. DOI: 10.3390/cancers16040752.

PP2A inhibitor SET promotes mTORC1 and Bmi1 signaling through Akt activation and maintains the colony-formation ability of cancer cells.

Kohyanagi N, Kitamura N, Ikeda S, Shibutani S, Sato K, Ohama T J Biol Chem. 2023; 300(1):105584.

PMID: 38141761 PMC: 10826185. DOI: 10.1016/j.jbc.2023.105584.

References

Dong J . Prevalent mutations in prostate cancer. J Cell Biochem. 2005; 97(3):433-47. DOI: 10.1002/jcb.20696. View

Valk-Lingbeek M, Bruggeman S, van Lohuizen M . Stem cells and cancer; the polycomb connection. Cell. 2004; 118(4):409-18. DOI: 10.1016/j.cell.2004.08.005. View

Chen Z, Trotman L, Shaffer D, Lin H, Dotan Z, Niki M . Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005; 436(7051):725-30. PMC: 1939938. DOI: 10.1038/nature03918. View

Liu G, Parant J, Lang G, Chau P, Chavez-Reyes A, El-Naggar A . Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet. 2004; 36(1):63-8. DOI: 10.1038/ng1282. View

Olsen J, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P . Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006; 127(3):635-48. DOI: 10.1016/j.cell.2006.09.026. View

Choudhary C, Olsen J, Brandts C, Cox J, Reddy P, Bohmer F . Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell. 2009; 36(2):326-39. DOI: 10.1016/j.molcel.2009.09.019. View

Bruggeman S, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J . Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 2007; 12(4):328-41. DOI: 10.1016/j.ccr.2007.08.032. View

Berger R, Febbo P, Majumder P, Zhao J, Mukherjee S, Signoretti S . Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004; 64(24):8867-75. DOI: 10.1158/0008-5472.CAN-04-2938. View

Pan C, Gnad F, Olsen J, Mann M . Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics. 2008; 8(21):4534-46. DOI: 10.1002/pmic.200800105. View

10.

Gray I, Stewart L, Phillips S, Hamilton J, Gray N, Watson G . Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer. 1998; 78(10):1296-300. PMC: 2063186. DOI: 10.1038/bjc.1998.674. View

11.

Olsen J, Vermeulen M, Santamaria A, Kumar C, Miller M, Jensen L . Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal. 2010; 3(104):ra3. DOI: 10.1126/scisignal.2000475. View

12.

Trotman L, Niki M, Dotan Z, Koutcher J, Di Cristofano A, Xiao A . Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003; 1(3):E59. PMC: 270016. DOI: 10.1371/journal.pbio.0000059. View

13.

Berezovska O, Glinskii A, Yang Z, Li X, Hoffman R, Glinsky G . Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle. 2006; 5(16):1886-901. DOI: 10.4161/cc.5.16.3222. View

14.

Lukacs R, Memarzadeh S, Wu H, Witte O . Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell. 2010; 7(6):682-93. PMC: 3019762. DOI: 10.1016/j.stem.2010.11.013. View

15.

Forrest M, Edwards S, Hamoudi R, Dearnaley D, Arden-Jones A, Dowe A . No evidence of germline PTEN mutations in familial prostate cancer. J Med Genet. 2000; 37(3):210-2. PMC: 1734542. DOI: 10.1136/jmg.37.3.210. View

16.

Weintz G, Olsen J, Fruhauf K, Niedzielska M, Amit I, Jantsch J . The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol. 2010; 6:371. PMC: 2913394. DOI: 10.1038/msb.2010.29. View

17.

Christensen G, Kelstrup C, Lyngso C, Sarwar U, Bogebo R, Sheikh S . Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics. 2010; 9(7):1540-53. PMC: 2938087. DOI: 10.1074/mcp.M900550-MCP200. View

18.

Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones R . Role of histone H2A ubiquitination in Polycomb silencing. Nature. 2004; 431(7010):873-8. DOI: 10.1038/nature02985. View

19.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

20.

Adams J, Harris A, Pinkert C, Corcoran L, Alexander W, Cory S . The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985; 318(6046):533-8. DOI: 10.1038/318533a0. View